



## REVA Medical Provides Quarterly Cashflow Report for the Quarter Ended 31 December 2018

**San Diego, California and Sydney, Australia** (Thursday, 31 January 2019 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to provide the attached Appendix 4C Quarterly Cashflow Report for the quarter ended 31 December 2018. The Appendix 4C is unaudited.

### About Fantom Encore

Fantom Encore is a sirolimus-eluting bioresorbable scaffold developed as an alternative to metallic stents for the treatment of coronary artery disease. After restoration of blood flow, bioresorbable scaffolds support the artery through the healing process and then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural function of the artery and reduce the risk of adverse events associated with a permanent metallic drug-eluting stent. Fantom Encore is made from Tyrocore, REVA’s proprietary tyrosine-derived polymer invented for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom Encore visible under x-ray fluoroscopy. Fantom Encore is designed with a market-leading thin strut profile while maintaining strength and with distinct ease-of-use features such as x-ray visibility and expansion with one continuous inflation.

### About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s products include the Fantom Encore and MOTIV bioresorbable vascular scaffolds for the treatment of coronary artery disease and below-the-knee peripheral artery disease, respectively. REVA is currently selling Fantom Encore in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy and Turkey and is in the process of commercializing Fantom Encore in seven additional countries. REVA is based in San Diego, California.

Fantom, Fantom Encore, MOTIV, and Tyrocore are trademarks of REVA Medical, Inc.

### Forward-Looking Statements

*This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the*

“SEC”) on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**United States****Investor & Media Enquiries:**

REVA Medical, Inc.  
Leigh Elkolli  
Chief Financial Officer  
+1 858-966-3018

David Schull  
Russo Partners  
+1 858-717-2310  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

**Australia****Investor Enquiries:**

Perpetuity Capital Pty Ltd  
Kim Jacobs  
+61 438 217 279  
Andrew Cohen  
+61 408 333 452

**Australia****Media Enquiries:**

Buchan Consulting  
Rebecca Wilson  
+61 3 9866 4722

For personal use only

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

REVA Medical, Inc.

**ABN**

ARBN 146 505 777

**Quarter ended ("current quarter")**

31 December 2018

Consolidated statement of cash flows	Current quarter (Q4) \$'000 USD	Year to date (12 months) \$'000 USD
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	211	644
1.2 Payments for		
(a) research and development	(526)	(2,909)
(b) product manufacturing and operating costs	(405)	(1,804)
(c) advertising and marketing	(281)	(511)
(d) leased assets	—	—
(e) staff costs	(1,993)	(9,169)
(f) administration and corporate costs	(887)	(3,175)
1.3 Dividends received (see note 3)	—	—
1.4 Interest received	4	76
1.5 Interest and other costs of finance paid	—	—
1.6 Income taxes paid	—	—
1.7 Government grants and tax incentives	—	—
1.8 Other (provide details if material)	(19)	802
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(3,896)</b>	<b>(16,046)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(19)	(839)
(b) businesses (see item 10)	—	—
(c) investments	—	—
(d) intellectual property	—	—
(e) other non-current assets	—	—

For personal use only

<b>Consolidated statement of cash flows</b>	<b>Current quarter (Q4) \$'000 USD</b>	<b>Year to date (12 months) \$'000 USD</b>
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	—	50
(b) businesses (see item 10)	—	—
(c) investments	—	1,470
(d) intellectual property	—	—
(e) other non-current assets	—	—
2.3 Cash flows from loans to other entities	—	—
2.4 Dividends received (see note 3)	—	—
2.5 Other (provide details if material)	—	—
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(19)</b>	<b>681</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	—	—
3.2 Proceeds from issue of convertible notes	—	—
3.3 Proceeds from exercise of share options	20	20
3.4 Transaction costs related to issues of shares, convertible notes or options	—	—
3.5 Proceeds from borrowings	—	—
3.6 Repayment of borrowings	—	—
3.7 Transaction costs related to loans and borrowings	—	—
3.8 Dividends paid	—	—
3.9 Other	—	—
<b>3.10 Net cash from / (used in) financing activities</b>	<b>20</b>	<b>20</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	7,094	18,544
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(3,896)	(16,046)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(19)	681
4.4 Net cash from / (used in) financing activities (item 3.10 above)	20	20
4.5 Effect of movement in exchange rates on cash held	—	—
<b>4.6 Cash and cash equivalents at end of quarter</b>	<b>3,199</b>	<b>3,199</b>

For personal use only

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$'000 USD</b>	<b>Previous quarter \$'000 USD</b>
5.1 Bank balances	3,049	6,944
5.2 Call deposits	150	150
5.3 Bank overdrafts	—	—
5.4 Other (provide details)	—	—
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3,199</b>	<b>7,094</b>

1.8 Reimbursement of leasehold improvements of corporate headquarters

<b>6. Payments to directors of the entity and their associates</b>	<b>Current quarter \$'000 USD</b>
6.1 Aggregate amount of payments to these parties included in item 1.2	69
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	—
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Australian Director fees (1 non-executive director)	USD \$14
U.S. Director fees (5 non-executive directors)	USD \$55

<b>7. Payments to related entities of the entity and their associates</b>	<b>Current quarter \$'000 USD</b>
7.1 Aggregate amount of payments to these parties included in item 1.2	—
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	—
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

For personal use only

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$'000 USD	Amount drawn at quarter end \$'000 USD
8.1 Loan facilities	—	—
8.2 Credit standby arrangements	—	—
8.3 Other (please specify)	—	—

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

9. <b>Estimated cash outflows for next quarter</b>	\$'000 USD
9.1 Research and development	500
9.2 Product manufacturing and operating costs	350
9.3 Advertising and marketing	—
9.4 Leased assets	—
9.5 Staff costs	1,600
9.6 Administration and corporate costs	700
9.7 Other	—
<b>9.8 Total estimated cash outflows</b>	<b>3,150</b>

10. <b>Acquisitions and disposals of business entities</b> (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	N/A	N/A
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

### Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Sign here:                     /s/ Leigh Elkolli                      
(Director/Company secretary)

Date:           30 January 2019          

Print name: Leigh Elkolli

For personal use only

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

For personal use only